NPS Pharmaceuticals to Host Conference Call to Discuss FDA Approval of Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome Business Wire BEDMINSTER, N.J. -- January 2, 2013 NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will host a conference call to discuss its commercialization plan for Gattex, including the cost of therapy, today at 5:00 p.m. Eastern Time. To participate in the conference call, dial (800) 706-7748 and use pass code 18085144. International callers may dial (617) 614-3473, using the same pass code. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar. For those unable to participate in the live call, a replay will be available at (888) 286-8010, with pass code 79197503, until midnight Eastern Time, January 16, 2013. International callers may access the replay by dialing (617) 801-6888, using the same pass code. The webcast will also be available through the NPS website for the same period. About NPS Pharmaceuticals NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. The company’s lead product, Gattex^® 0.05 mg/kg/d (Teduglutide [rDNA origin]) for Injection, for subcutaneous use is FDA-approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS is also developing Natpara^® (rhPTH[1-84]) for the treatment of adult hypoparathyroidism and expects to submit its Biologic License Application (BLA) to the FDA in mid-2013. NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Takeda GmbH. Contact: NPS Pharmaceuticals, Inc. Gail Brophy, 908-450-5335
NPS Pharmaceuticals to Host Conference Call to Discuss FDA Approval of Gattex® (teduglutide [rDNA Origin]) for Injection for
Press spacebar to pause and continue. Press esc to stop.